-+ 0.00%
-+ 0.00%
-+ 0.00%

Hengrui Pharma wins China approval for camrelizumab-famitinib combo as 1L cervical cancer treatment

PUBT·07/23/2026 12:32:44
Listen to the news
Hengrui Pharma wins China approval for camrelizumab-famitinib combo as 1L cervical cancer treatment
  • China’s NMPA cleared camrelizumab injection with famitinib malate for first-line recurrent or metastatic cervical cancer in PD-L1-positive patients.
  • The decision upgrades the regimen from second-line to first-line use in advanced cervical cancer.
  • Approval follows a phase III trial showing median OS of 35.8 months vs 23.6 months on chemotherapy in the PD-L1-positive subgroup (HR 0.634).


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260723-12254653), on July 23, 2026, and is solely responsible for the information contained therein.